Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapyKelley M. Kidwell, N. Lynn Henry, Steven E. Harte et al.|Cancer|2014Cited by 98
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast CancerKunal C. Kadakia, N. Lynn Henry, Claire Snyder et al.|The Oncologist|2016Cited by 76
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancerN. Lynn Henry, David A. Flockhart, Todd C. Skaar et al.|Breast Cancer Research and Treatment|2013Cited by 64
Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnoverSteffi Oesterreich, David A. Flockhart, N. Lynn Henry et al.|Breast Cancer Research and Treatment|2015Cited by 35
Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancerDaniel L. Hertz, James M. Rae, Kelley M. Kidwell et al.|The Pharmacogenomics Journal|2016Cited by 25